867 related articles for article (PubMed ID: 17283905)
1. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
2. Pericellular proteases in angiogenesis and vasculogenesis.
van Hinsbergh VW; Engelse MA; Quax PH
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):716-28. PubMed ID: 16469948
[TBL] [Abstract][Full Text] [Related]
3. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
Kim MH
J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
[TBL] [Abstract][Full Text] [Related]
4. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
Maillard C; Jost M; Rømer MU; Brunner N; Houard X; Lejeune A; Munaut C; Bajou K; Melen L; Dano K; Carmeliet P; Fusenig NE; Foidart JM; Noel A
Neoplasia; 2005 Jan; 7(1):57-66. PubMed ID: 15720817
[TBL] [Abstract][Full Text] [Related]
5. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis.
Forget MA; Desrosiers RR; Béliveau R
Can J Physiol Pharmacol; 1999 Jul; 77(7):465-80. PubMed ID: 10535707
[TBL] [Abstract][Full Text] [Related]
6. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
7. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.
Mueller MM; Fusenig NE
Differentiation; 2002 Dec; 70(9-10):486-97. PubMed ID: 12492491
[TBL] [Abstract][Full Text] [Related]
8. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
[TBL] [Abstract][Full Text] [Related]
9. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A
Oncogene; 2004 Sep; 23(41):6986-90. PubMed ID: 15286708
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of proteases as anticancer drugs.
Jedinak A; Maliar T
Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
[TBL] [Abstract][Full Text] [Related]
11. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
13. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
Yoon WH; Jung YJ; Kim TD; Li G; Park BJ; Kim JY; Lee YC; Kim JM; Park JI; Park HD; No ZS; Lim K; Hwang BD; Kim YS
Clin Cancer Res; 2004 Jul; 10(13):4517-26. PubMed ID: 15240544
[TBL] [Abstract][Full Text] [Related]
14. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
17. Neutral proteinases and their inhibitors in the loosening of total hip prostheses.
Takagi M
Acta Orthop Scand Suppl; 1996 Oct; 271():3-29. PubMed ID: 8975533
[TBL] [Abstract][Full Text] [Related]
18. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
20. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
